Treatment with Intravenous Immunoglobulins IVIG will improve symptoms and significantly slow the disease progression.
Research for alternative treatments is ongoing. CNO is involved in clinical trials testing new therapies (complement inhibitors) for MMN.
Target Population: Men and women over 18 with a diagnosis of MMN that satisfies the European diagnostic criteria of 2010.
For more information contact Victorine Sikati Foko.
Currently, there are no ongoing studies being conducted.
No available completed studies.
